Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy.